MakeO Secures Rs 90 Crore to Scale Aesthetic Healthtech Solutions
Mumbai-based healthtech startup MakeO, the parent company behind popular consumer brands toothsi and skinnsi, has successfully closed a fresh funding round of Rs 90 crore. This capital injection marks a significant milestone for the company as it continues to bridge the gap between clinical-grade aesthetic treatments and consumer convenience in the Indian market.
MakeO has carved a unique niche for itself by offering a comprehensive suite of dental, skin, and hair care solutions. By leveraging a hybrid model that combines at-home services with specialized physical clinics, the startup has effectively democratized access to professional-grade aesthetic procedures. This latest infusion of capital is expected to bolster the company’s operational footprint and enhance its technological infrastructure, allowing it to reach a broader demographic across India.
Strategic Backing for Future Growth
The funding round was led by Singularity AMC, reflecting strong investor confidence in MakeO’s business model and its ability to scale in the competitive healthtech landscape. The round also saw participation from notable entities including the DSP family office, Genesis, and Unispace Ventures. This diverse group of investors brings not only capital but also strategic expertise that will be instrumental as MakeO navigates its next phase of growth.
As the demand for personalized, tech-enabled wellness and aesthetic treatments continues to surge in India, MakeO remains well-positioned to capitalize on these shifting consumer preferences. By integrating advanced diagnostics with a seamless user experience, the company is setting a new standard for how Indians approach dental and dermatological care. With this fresh liquidity, the leadership team is likely to focus on expanding its service portfolio and deepening its presence in Tier-1 and Tier-2 cities, ensuring that high-quality aesthetic care remains accessible to a growing middle-class population.
For the Indian startup ecosystem, this deal serves as a positive indicator that investors remain bullish on high-growth healthtech ventures that demonstrate clear unit economics and a strong value proposition for the end consumer.